new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




  

Amicus Therapeutics Inc patents

Recent patent applications related to Amicus Therapeutics Inc. Amicus Therapeutics Inc is listed as an Agent/Assignee. Note: Amicus Therapeutics Inc may have other listings under different names/spellings. We're not affiliated with Amicus Therapeutics Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Amicus Therapeutics Inc-related inventors




Date Amicus Therapeutics Inc patents (updated weekly) - BOOKMARK this page
03/02/17Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
03/02/17High concentration alpha-glucosidase compositions for the treatment of pompe disease
02/16/17Methods for treatment of fabry disease
02/16/17New preparing isofagomine and its derivatives
02/02/17Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase
01/26/17Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
11/10/16Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
11/10/16Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
10/06/16Pharmacological chaperones for treating obesity
06/30/16Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
05/12/16Chemical crosslinkers
02/25/16Method for the treatment of pompe disease using 1-deoxynojirimycin derivatives
01/14/16Dosing regimens for treating and/or preventing cerebral amyloidoses
12/31/15Method for treating cerebral amyloid angiopathy using pharmacological chaperones to increase the activity of gangliosidases
12/10/15Stable parenteral dnj compositions
12/10/15Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
09/24/15Compounds and methods for treating or preventing disease conditions associated with alpha-1-antirypsin
08/27/15Methods for treatment of fabry disease
08/13/15Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of mps iiic
08/06/15Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
06/25/15Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
05/14/15Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
03/26/15Dosing regimens for the treatment of pompe disease
02/19/15Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
02/12/15High concentration alpha-glucosidase compositions for the treatment of pompe disease
01/22/15Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase
07/24/14Method to predict response to pharmacological chaperone treatment of diseases
03/27/14Novel compositions for preventing and/or treating lysosomal storage disorders
03/20/14Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
09/26/13Compounds and methods for treating or preventing disease conditions associated with alpha-1-antitrypsin
04/25/13Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity
12/06/12Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
11/08/12Quantitation of gl3 in urine
08/30/12Methods for treatment of fabry disease
03/15/12Mouse model for pompe disease and methods of use thereof
11/03/11Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
09/01/11Method to predict response to pharmacological chaperone treatment of diseases
08/04/11Treatment of pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
06/23/11Method to predict response to pharmacological chaperone treatment of diseases
06/09/11Assays for diagnosing and evaluating treatment options for pompe disease
05/05/11Assays for diagnosing and evaluating treatment options for fabry disease
05/05/11Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
04/21/11Novel compositions for preventing and/or treating lysosomal storage disorders
04/21/11Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
03/03/11Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase
10/21/10Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
10/14/10Methods for preventing and/or treating lysosomal storage disorders
10/14/10Methods for preventing and/or treating degenerative disorders of the central nervous system
08/05/10Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
08/05/10Use of substrates as pharmacological chaperones
07/29/10Hydroxy piperidine derivatives to treat gaucher disease
07/15/10Periodic acid-schiff staining with detection in the infrared range
06/24/10New preparing isofagomine and its derivatives
05/13/10Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
05/06/10Method for the treatment of fabry disease using pharmacological chaperones
04/29/10Multiple compartment dosing model
07/09/09Tartrate salt of isofagomine and methods of use







ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Amicus Therapeutics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Amicus Therapeutics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';